NavigAID SSc: Patient stratification for systemic sclerosis (SSc)

NavigAID SSc is a disease stratification array designed to support pharmaceutical and biotechnology companies with their SSc drug development efforts by defining specific disease subgroups via the straightforward measurement of serum autoantibodies.

SSc is a rare, complex autoimmune disease that manifests as progressive fibrosis of the skin and internal organs. Despite numerous efforts in recent years, no drug has been approved to date for the treatment of SSc, with the disease’s remarkably heterogeneous nature being the main hurdle for successful drug development.

Protagen’s NavigAID SSc array has been specifically developed to tackle this heterogeneity, and facilitate the clinical development of novel drug therapies by employing autoantibody biomarkers identified by Protagen’s SeroTag® platform.

NavigAID SSc is a disease stratification array designed to support pharmaceutical and biotechnology companies with their SSc drug development efforts by defining specific disease subgroups via the straightforward measurement of serum autoantibodies.

The tool facilitates differential diagnosis, risk stratification and prediction of organ involvement to support the development of a precision medicine approach in SSc and will benefit any new clinical development program.

To find out more about how NavigAID SSc could help to develop more targeted, effective therapies, download the white paper.

NavigAID SLE is a stratification tool that separates and defines subgroups of SLE patients in order to overcome disease heterogeneity, and support biotechnology and pharmaceutical companies with their drug development programs.

NavigAID SjS is a patient stratification tool that measures serum autoantibody levels in Sjögren’s patients, in order to help to characterize the immunological processes underlying the disease and help facilitate the development of more effective therapies.

 

NavigAID RA is a patient stratification tool that measures autoantibodies in serum to help group patients based on the immunological processes underlying their condition, to help advance the development of precision medicine treatments and approaches.

 

Get in touch

Improving the treatment of cancer and autoimmune disease is our passion, and we always welcome the chance to discuss these topics with current and prospective customers, patients and clinicians alike.

We sometimes like to share the latest industry insights and company news, would you like to be added to our database?

15 + 15 =

Copyright © 1997-2018
Protagen AGDortmund, Germany